Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talquetamab Plus Concomitant Priming Radiotherapy in Multiple Myeloma With Extramedullary Disease
NCT06572605Phase 2Suspended
- Sponsor
- City of Hope
- Start
- Aug 2025
- Primary completion
- Jan 2030
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of talquetamab in multiple myeloma (MM), sponsored by City of Hope. Started Aug 2025; status: suspended.
02
Drugs
talquetamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06572605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06572605.